Business
KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
FRAMINGHAM, Mass. & SALISBURY, England, March 25, 2026--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today reported financial results for the eight months ended December 31, 2025, and provided a corporate update. As previously announced, the Company changed its fiscal year from ending April 30 of each year to ending December 31 of each year. There was an eight-month transition period from May 1, 2025 to December 31, 2025 and these results are presented within the condensed consolidated financi
About this update from Kaken Pharmaceutical Co., Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":474,"url":"https://media.zenfs.com/en/business-wire.com/55de309a290e9abfb410ee3ab693863c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Y.o.pi6fOLyhCBApOkvPFA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk0OA--/https://media.zenfs.com/en/business-wire.com/55de309a290e9abfb410ee3ab693863c","width":480,"height":474}},"lazy":false},{"type":"text","content":"$49.1 million global net product revenue of EKTERLY® (sebetralstat) for the eight months ended December 31, 2025","length":112,"tagName":"p","attribs":{}},{"type":"text","content":"1,702 patient start forms received in the US from launch through end of February, reflecting continued rapid adoption of first and only oral on-demand treatment for hereditary angioedema (HAE)","length":192,"tagName":"p","attribs":{}},{"type":"text","content":"EKTERLY launched in Japan by partner Kaken Pharmaceutical Co., LTD","length":66,"tagName":"p","attribs":{}},{"type":"text","content":"Company to host conference call today at 8:30am ET","length":50,"tagName":"p","attribs":{}},{"type":"text","content":"FRAMINGHAM, Mass. & SALISBURY, England, March 25, 2026--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today reported financial results for the eight months ended December 31, 2025, and provided a corporate update. As previously announced, the Company changed its fiscal year from ending April 30 of each year to ending December 31 of each year. There was an eight-month transition period from May 1, 2025 to December 31, 2025 and these results are presented within the condensed consolidated financial statements.","length":535,"tagName":"p"},{"type":"text","content":""As we enter the next phase of the EKTERLY launch, we are seeing the benefits of disciplined execution and increasing real-world experience with the first and only oral on-demand therapy for HAE," said Ben Palleiko, CEO of KalVista. "The trend towards high adoption continues, as evidenced by steady underlying demand and increasing utilization from patients seeking the benefits of an oral on-demand option. Internationally, EKTERLY’s early performance in Germany, the recent launch in Japan by our partner Kaken Pharmaceutical and our plans to initiate additional market...